Resources/
Phil Blog

Phil Blog

What Makes Phil’s Prior Authorization Process Unique?

The prior authorization process (PA) presents a significant (and growing) roadblock for healthcare providers trying to get a patient started on a prescription therapy they deem best. In general, a PA requirement affects patients' experience with their healthcare. It represents a length of time – and the associated frustration – they must wait to receive their medication or go without the treatment they have been introduced to by their provider and may desperately need

Transforming the Prior Authorization Process: How Feedback Loops can Improve Patient Access to Life Sciences Brands

The use of prior authorization (PA) to control the utilization of prescription drugs, especially specialty medications, is growing, with 79% of medical practices reporting that PA requirements increased between 2021 and 2022. By design, the PA process is a barrier to medication access – it can leave patients waiting for days, weeks, or even months for approval, and coverage denial may occur despite a therapy being appropriately prescribed. The negative consequences of delaying treatment are well documented, yet more than 8 out of 10 patients still experience delays accessing their medications for reasons such as cost and insurance challenges

Prior Authorizations: What Pharmaceutical Manufacturers Need to Know

As healthcare costs have escalated over the last several decades, public and private medical insurers have introduced different utilization management (UM) strategies to control healthcare expenditures. The proliferation of higher-cost specialty medications has accelerated the use of drug UM tools to control access, with prior authorization (PA) being the most common today. From the payer's perspective, PAs are necessary to improve quality of care and protect patients’ safety

Optimizing life sciences field teams

A persistent challenge for life sciences manufacturers is growing access and affordability obstacles, exacerbated by hard-to-enter formularies and rigorous utilization management (UM) practices. Payers are tightening the screws year over year with new cost containment strategies. Where there used to be hoops, they are now on fire, making it more difficult than ever to ensure reimbursement at the pharmacy

Phil Inc Adds Additional Duchesnay USA Women’s Healthcare Product to PhilRx

In 2018, after launching Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), Duchesnay USA utilized a combination of retail and specialty pharmacies to support patient access to the medication. This channel strategy experienced challenges, particularly around patient experience and prescription coverage rates. In 2022, the Duchesnay team engaged Phil Inc looking for ways to address their patient experience and access challenges: Shipping time: Patients experienced delays to therapy after paying their out of pocket expenses